API (Applied Pharmaceutical Innovation)

Do you know a leader, team or company making exceptional contributions to science, technology and innovation across Alberta? Nominations for the 2026 ASTech Awards are now open! Whether you’re putting your own work forward or recognizing someone else’s achievements, being nominated is a great way to celebrate and showcase your contributions. Submit your nominations now: https://lnkd.in/giZr2SWZ Recommendation Deadline: April 10, 2026 Full Nomination Deadline: May 4, 2026

Yesterday, our Chief Scientific Officer, Sir Michael Houghton, alongside members of our research and technical team welcomed Emeritus Professor Michael Good AO and Business Manager (Commercial), Eloise Keeffe from the Griffith University Institute for Biomedicine and Glycomics to the Biotechnology Business Development Centre in Edmonton Research Park (ERP). Dr. Good works with Sir Houghton, leading one of the key CCDI projects at the University of Alberta’s Li Ka Shing Institute of Virology (AVI). He shared insights into his work on developing a peptide-based vaccine targeting Group A Streptococcus, a common bacterium that can lead to illnesses ranging from Strep A tonsillitis to serious conditions such as rheumatic heart disease and invasive Strep A. We’re pleased to host a tour of the facility, showcasing some of our R&D spaces and GMP suites, and provide an overview of our specialized equipment and capabilities at the Critical Medicines Production Centre, which can support large-scale manufacturing of critical medicines globally. Thank you to Dr. Good and Eloise for visiting and sharing your incredible work. We look forward to staying connected and exploring collaboration opportunities to advance research and innovation. Andrew MacIsaac Hans-Herwig Bauer Daren Ure Tamana Yousof, PhD

🎥 Our CBC feature is now live! Our CEO, Andrew MacIsaac joined Vimy Pharma co-founders Dave Suchon and Farris Smith to talk about our work to produce Canada-made generic semaglutide at our Critical Medicines Production Centre (CMPC). Our specialized facility is custom-designed to provide security of supply of critical medicines and a much needed made-in-Canada option for pharmaceutical companies and innovators. Watch the full video👇 https://bit.ly/47SFvhs

POV: You’re developing a medical device and looking to bring your product to the Canadian market. Where do you start? 🧐    In our first issue of Innovation Translated, we’re zeroing in on one of the foundational steps in the regulatory journey: 𝗽𝗿𝗼𝗱𝘂𝗰𝘁 𝗰𝗹𝗮𝘀𝘀𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻. Our subject matter expert and Regulatory Specialist, John Huang, breaks down:    1️⃣ Why product classification is a critical first step in the regulatory process  2️⃣ The medical device classifications in Canada  3️⃣ Why product classification matters early    Find out below and subscribe👇 #MedicalDevices #Classification #lifesciences

Introducing: Innovation Translated 🧬 A newsletter series offering insights and real-world perspectives on what it takes to move discoveries from the lab to market. Designed to be a knowledge hub for the life sciences community, each issue is backed by subject matter experts, providing clarity and practical tips for navigating pathways and challenges in the life sciences sector.   Read on to discover some of the topics our experts will explore across key stages of the innovation journey, including:    1️⃣ Discovery and Development  2️⃣ Regulatory Strategy and Compliance  3️⃣ Clinical and Quantitative Solutions  4️⃣ Clinical and Commercial Manufacturing   Subscribe below and be the first to know about our latest issue 📩

If you know Nimble Science, you’ve heard about their groundbreaking innovation that’s transforming digestive health diagnostics.    Through their SIMBA capsule and GI platform, they support the collection, analysis and interpretation of novel data from the small intestine, enabling breakthroughs to improve care for gut health. But what kind of mindset did it take for this technology to be possible?     Hear from Sabina Bruehlmann, Co-Founder and CEO of Nimble Science, as she walks through her entrepreneurial journey with Leah Sarich in an episode of The Founder Mindset podcast 👇 #AlbertaFounders #lifesciences #MedicalDevice 

Did you know? Earlier this year, the FDA released a revised Guidance on Clinical Decision Support (CDS) Software.     The document clarifies the criteria for software functions that are excluded from the device definition (Non-Device CDS), expanding exemptions to help promote innovation in digital health tools.    Key aspects include:    ✅ Four criteria for Non-Device CDS   - the software must inform clinical management (not drive it)   - be based on medical information about a patient   - enables independent review by healthcare professionals (HCPs)   - be intended for HCP use    ✅ Examples of exempt function: This includes software providing prioritized treatment options with full basis disclosure vs. regulated device functions.    ✅ Continued application of digital health policies to device software,  with enforcement discretion for low-risk cases.    Read the full guidance document: https://lnkd.in/g24dDWah

Congratulations to Voyageur Pharmaceuticals Ltd. on this exciting milestone! In this new collaboration, Voyageur will support Bayer’s research and development aimed at evaluating potential future production of iodine for use in contrast media drugs. As a proud partner, we’re excited to celebrate their growing partnerships and continued efforts to strengthen North America’s contrast media supply chain. 

Women founders in the life sciences are doing more than building companies They’re advancing discoveries forward, challenging the status quo and continuing to strengthen and diversify the future of health innovation.    On International Women’s Day, we’re inspired to highlight the impact and contributions of women-led companies we support through the Health Innovation Hub at UAlberta. From developing tools that help better manage women’s health including prenatal detection of congenital heart disease (CHD) and menopause care, to advancing innovations in respiratory health, caregiver support and accessibility, these women founders are addressing critical gaps across the health system. We’re proud to continue supporting these women as they work toward a more inclusive and healthier future for our communities.    #InternationalWomensDay #WomenInLifeSciences #WomenFounders 

Yesterday, we joined leaders from across our life sciences community at BioAlberta’s Annual Policy Forum to discuss emerging trends and opportunities shaping health innovation in the province.    It was great to hear from health and industry leaders, connect with partners and see new collaborations forming to strengthen research and innovation across the sector.    A big congratulations to the Alberta Cancer Foundation on their new partnerships to advance the Precision Analytics Program, an initiative created in collaboration with Cancer Care Alberta that is creating a roadmap to improve patient outcomes across the province.    Thank you BioAlberta for bringing the community together! We’re proud to support and continue working alongside partners to advance health innovation and patient care in Alberta.